C. 24

To: Board of SupervisorsFrom: William Walker, M.D., Health Services DirectorDate: January 23, 2018



Contra Costa County

Subject: Purchase Order Amendment with Abbott Laboratories, Inc.

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent to execute, on behalf of the Health Services Director, an amendment to Purchase Order #F01951 with Abbott Laboratories, Inc., to increase the payment limit by \$35,000 for a new payment limit of \$155,000 for the purchase of testing supplies for the laboratory at the Contra Costa Regional Medical Center (CCRMC), with no change in the original term of September 1, 2015 through August 31, 2018.

FISCAL IMPACT:

100% funding is included in the Hospital Enterprise Fund I budget.

BACKGROUND:

Abbott Laboratories, Inc., has been providing testing products and reagents to CCRMC for more than eleven years. Recently, the CCRMC medical staff began using Abbott's single use lactic acid testing cartridges, which can reduce the time needed to obtain test results for patients with possible sepsis to three minutes.

The use of this product has improved patient care, but has contributed to the need for

A	PPROVE	OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR RECOMMENDATION OF BOARD COMMITTEE		
Action of Board On: 01/23/2018 APPROVED AS RECOMMENDED OTHER		
Clerks Notes:		
VOTE OF SUPERVISORS		
	John Gioia, District I Supervisor Candace Andersen, District II Supervisor Diane Burgis, District III Supervisor Karen Mitchoff, District IV Supervisor Federal D. Glover, District V Supervisor	I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown. ATTESTED: January 23, 2018 David Twa, County Administrator and Clerk of the Board of Supervisors By: June McHuen, Deputy
Contact: Anna Roth, 925-370-5101		

additional funds to cover the testing supplies that CCRMC will need throughout the term of this purchase order.

CONSEQUENCE OF NEGATIVE ACTION:

If this amendment is not approved, the CCRMC laboratory will not have access to testing supplies and reagents needed to treat patients, thus affecting patient care.